Clinical trials: Pancreas Carcinoma
Pancreatic Cancer
Changes in Muscle Tissue in Patients With Pancreatic Cancer
RATIONALE: Measuring changes in muscle tissue in patients with cancer may help doctors predict how well patients will respond to treatment, and may help the study of cancer in the future.
- Trial name
- NCT00369460
- Testing
- physiologic testing
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Carcinoma, Male Breast Carcinoma
Access to Genetic Testing in Underserved Patients With Cancer
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider.
- Conditions
- Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma
- Trial name
- NCT06422455
- Testing
- Best Practice, Educational Intervention, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Pancreatic Carcinoma, Biliary Obstruction
Combined Stent Insertion and HIFU Ablation for Pancreatic Carcinoma With Biliary Obstruction
The purpose of this study is to compare the clinical effectiveness and long-term outcomes between patients with pancreatic carcinoma and biliary obstruction who are treated by stent insertion with or without high-intensity…
- Trial name
- HIFU (NCT03962478)
- Testing
- biliary stent and high-intensity focused ultrasound ablation system, biliary stent
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Xuzhou Central Hospital
Cancer of Pancreas
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
Pancreatic cancer is one of the deadliest tumor types, there is no effective treatment method clinically. Recently radical surgical resection is recommended for this cancer, How to improve the survival rate of patients is the…
- Trial name
- NCT03278015
- Testing
- Nab-paclitaxel plus Gemcitabine, Gemcitabine monotherapy, S-1 monotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Advanced Solid Tumors
A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
The purpose of this study is to find a safe, tolerable, and efficacious dose of BMS-986466 when given orally, in combination with adagrasib with or without cetuximab in participants with advanced KRAS G12C-mutant non-small cell…
- Trial name
- NCT06024174
- Testing
- BMS-986466, Adagrasib, Cetuximab
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 5 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03153410
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ovarian Cancer, Prostate Cancer
Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes
This study will evaluate patients' experiences with having gynecologic or prostate medical oncologists and surgeons offer them genetic testing, and having genetic counselors return the test results to patients over the telephone.
- Conditions
- Ovarian Cancer, Prostate Cancer, Pancreas Cancer
- Trial name
- NCT02917798
- Testing
- Assessments
- Where
- 5 sites in United States
- Volunteers
- 1,047 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Neoplasms, Cancer of the Pancreas
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Background: In 2009, 49,096 patients were diagnosed with pancreatic cancer. Pancreatic cancer carries a poor prognosis with an overall 5-year relative survival rate of 5.6%.
- Conditions
- Pancreatic Neoplasms, Cancer of the Pancreas, Neoplasms Pancreatic, Pancreatic Cancer
- Trial name
- NCT01313416
- Testing
- CT-011, Gemcitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Augusta University
Pancreas Cancer, Pancreatic Cancer
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
- Conditions
- Pancreas Cancer, Pancreatic Cancer, Cancer of the Pancreas
- Trial name
- NCT04542291
- Testing
- Dapagliflozin, BIOSENSE meters
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Cancer, Breast, Cancer, Lung
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid…
- Conditions
- Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus
- Trial name
- NCT05830097
- Testing
- CBP-1019
- Where
- 5 sites in United States, China
- Volunteers
- 260 people
- Sponsor
- Coherent Biopharma (Hefei) Co., Ltd.
Cancer, Cancer Metastatic
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
The purpose of this prospective, interventional, single-arm pilot study is to evaluate whether virtually delivered group-based physical activity is feasible for adolescent and young adult (AYA) cancer survivors.
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer
- Trial name
- NCT05131815
- Testing
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Pancreatic Cancer, Adenocarcinoma
Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery
This study is being done to investigate another way of evaluating margin status after pancreatectomy by using cytopathology (slide interpretation) as compared to the traditional method of surgical pathology
- Trial name
- NCT01646697
- Testing
- cytology specimen collection procedure
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Efficacy and Safety
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
The purpose of this study is to evaluate the efficacy and safety of HR070803 in Combination With Oxaliplatin plus Tegafur compared to HR070803 in combination with oxaliplatin, 5-fluorouracil/leucovorin (5FU/LV) treatment as…
- Trial name
- NCT06383078
- Testing
- HR070803, Oxaliplatin, Tegafur
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Pancreatic Cancer Resectable
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.
- Trial name
- NCT06809374
- Testing
- gemcitabine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Kochi University
Adenocarcinoma Pancreas
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
This is a pilot study to evaluate the role of the addition of CP870, 893 to the neoadjuvant and adjuvant setting for patients with resectable pancreatic cancer.
- Trial name
- NCT01456585
- Testing
- Gemcitabine, CP-870,893
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Tumors
One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy
This study will include a one time intravenous (IV) infusion of Clostridium novyi-NT (C. novyi-NT) spores to treat solid tumors which have not responded to standard therapy.
- Trial name
- NCT00358397
- Testing
- Clostridium novyi-NT spores
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Neoplasm of Uncertain Behavior Head
Risk Factors for Achieving TO After LDPPHR-t
This is a single, retrospective, observational study to investigate the risk factors for achieving textbook outcome after laparoscopic duodenum-preserving total pancreatic head resection.
- Trial name
- NCT05569343
- Testing
- No intervention
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Tongji Hospital
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
- Trial name
- STELLAR-311 (NCT06943755)
- Testing
- Zanzalintinib, Everolimus
- Where
- 135 sites in United States, Australia and 16 more
- Volunteers
- 440 people
- Sponsor
- Exelixis
Pancreatic Carcinoma
Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer
The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for locally advanced pancreatic carcinoma (LAPC)
- Trial name
- NCT04082455
- Testing
- carbon ion radiotherapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Shanghai Proton and Heavy Ion Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.